Fast-Track Rational & Structure-Based Molecular Glues from Discovery to Clinic by Improving PPI Prediction, Hit Discovery & Lead Optimization Whilst Overcoming PKPD & Toxicity Challenges to Finally Drug the Undruggable

logo banner 1

Welcome to the 3rd Molecular Glue Drug Development Summit

Pioneering Rationally Designed Molecular Glue Degraders for Clinical Application

Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 has seen a multitude of collaborations, with Takeda and Degron Therapeutics entering a deal worth $1.2 billion.

The 3rd Molecular Glue Drug Development Summit returns as the only industry-dedicated forum bringing together 90+ experts as they showcase the latest advancements and breakthroughs in molecular glue drug development through discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies, to streamline discovery and development of safe and effective glues.

DOWNLOAD THE BROCHURE

Brochure image

2025 World-Class Speaker Faculty Includes:

Rana Quraishi

CEO - Isoprene Pharmaceuticals

Yao Wang

Chief Medical Officer - Kangpu Biopharmaceuticals

Matthias Brand

Chief Technology Officer - Proxygen GmbH

Rick Ewing

Vice President & Head of Chemistry - Rapafusyn Pharmaceuticals

Matthew Hayward

Vice President of Drug Discovery - Magnet Biomedicine

Felix Hausch

Professor - Technical University of Darmstadt

What’s New for 2025?

21 (4)

SCIENTIFIC POSTER SESSION

21 (2)

INTERACTIVE PANEL DISCUSSIONS

3 (1)

DAYS OF
IN-DEPTH CONTENT

21 (3)

DEEP DIVE CASE STUDIES

21 (7)

WORLD-CLASS SPEAKERS

2025 Attending Companies Include:

mol glue
Other Events in the Small Molecules & TPD World Series: